JHL Biotech Reports Dosing of its First Patient with JHL1266 (biosimilar, denosumab) in P-I Study in Australia

 JHL Biotech Reports Dosing of its First Patient with JHL1266 (biosimilar, denosumab) in P-I Study in Australia

JHL Biotech’s Trastuzumab Biosimilar (JHL1188) Receives CHMP Positive Scientific Advice to Treat Breast Cancer

Shots:

  • The study involves assessing of JHL1266 vs Prolia sourced from the EU and the US in healthy human subjects evaluating its PK, PD, and immunogenicity
  • The JHL1266 is proved to be a milestone and an initiative in bringing safe, effective, and high-quality biologics
  • JHL1266 is a mAb targeting RANKL works by inhibition of developed osteoclasts and then preventing break down of bones in the human body and is targeted for osteoporosis, bone metastases, giant cell tumors of bone, and other treatment-induced bone loss

Click here to read full press release/ article | Ref: JHL | Image: Behance

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post